Evidence map›Paper›PMID 35822698›Full record

ArticleCNS neuroscience & therapeutics2022

Effects of α5 GABA

Jovana Aranđelović, Anja Santrač, Bojan Batinić, Lidija Todorović, Vladimir Stevanović, Veera Venkata Naga Phani Babu Tiruveedhula, Dishary Sharmin, Farjana Rashid, Boban Stanojević, James M Cook and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CNS neuroscience & therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Effects of α5 GABACNS neuroscience & therapeutics · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Jovana AranđelovićDepartment of Pharmacology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
Anja SantračDepartment of Pharmacology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
Bojan BatinićDepartment of Physiology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
Lidija TodorovićLaboratory for Radiobiology and Molecular Genetics, Vinča Institute of Nuclear Sciences, National Institute of thе Republic of Serbia, University of Belgrade, Belgrade, Serbia.
Vladimir StevanovićDepartment of Pharmacology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
Veera Venkata Naga Phani Babu TiruveedhulaDepartment of Chemistry and Biochemistry, Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
Dishary SharminDepartment of Chemistry and Biochemistry, Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
Farjana RashidDepartment of Chemistry and Biochemistry, Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
Boban StanojevićLaboratory for Radiobiology and Molecular Genetics, Vinča Institute of Nuclear Sciences, National Institute of thе Republic of Serbia, University of Belgrade, Belgrade, Serbia.
James M CookDepartment of Chemistry and Biochemistry, Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
Miroslav M SavićDepartment of Pharmacology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.ORCID 0000-0002-6934-9193
University of Belgrade · RSUniversity of Wisconsin–Milwaukee · USKing's College London · GB

Funding

Synthesis of Alpha2/Alpha3 GABA Agonists to Treat Neuropathic PainR01NS076517 · NINDS · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 2012 to 2015
$1.3M
NINDS NIH HHS R01 NS076517
6 · The paper itself

Abstract

aimsGABAergic modulation involved in cognitive processing appears to be substantially changed in Alzheimer's disease (AD). In a widely used 5xFAD model of AD, we aimed to assess if negative and positive allosteric modulators of α5 GABA

methodsAfter 10-day treatment with PAM, NAM, or solvent, 6-month-old transgenic and non-transgenic 5xFAD mice underwent testing in a behavioral battery. Gene expressions of IL-1β, IL-6, TNF-α, GFAP, and IBA-1 were determined in hippocampus and prefrontal cortex by qPCR.

resultsPAM treatment impaired spatial learning in transgenic females compared to solvent-treated transgenic females, and social recognition in transgenic and non-transgenic males. NAM treatment declined social interaction in transgenic and non-transgenic males, while had beneficial effect on cognitive flexibility in non-transgenic males compared to solvent-treated non-transgenic males. Transgenic animals have not fully displayed cognitive symptoms, but neuroinflammation was confirmed. NAM reduced proinflammatory gene expressions in transgenic females and astrogliosis in transgenic males compared to pathological controls.

conclusionPAM and NAM failed to exert favorable behavioral effects in transgenic animals. Suppression of neuroinflammation obtained with NAM calls for more studies with GABAergic ligands in amyloid beta- and/or tau-dependent models with prominent neuroinflammation.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsDisease Models, AnimalFemalegamma-Aminobutyric AcidInterleukin-6MaleMemoryMiceMice, TransgenicNeuroinflammatory DiseasesReceptors, GABA-ASocial InteractionSolventsTumor Necrosis Factor-alphaAmyloid beta-Peptidesgamma-Aminobutyric AcidInterleukin-6Receptors, GABA-ASolventsTumor Necrosis Factor-alpha5xFADAlzheimer's diseasecognitionneuroinflammationα5 GABAA receptor modulation

Identifiers

PMID35822698
PMCPMC9532908
OpenAlexW4285086102

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.